FDA Rejects Merck's Combo Cholesterol Drug For Now

Law360, New York (March 5, 2012, 4:17 PM EST) -- Merck & Co. Inc. said Monday that federal regulators have rejected its new cholesterol drug combining the drug giant's own Zetia product with generic Lipitor, telling Merck that they need additional data about the drug before approving it.

Merck said it is planning to submit additional information about the tablets containing both Zetia, known chemically as ezetimibe, and atorvastatin, or generic Lipitor, to the U.S. Food and Drug Administration. The company hasn’t set a timeline for those actions but said that new data on the drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.